These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17512452)

  • 1. Emerging targeted therapies for breast cancer.
    Arnedos M; Seidman AD
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):321-40. PubMed ID: 17512452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies in breast cancer: where are we now?
    Di Cosimo S; Baselga J
    Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapies: a nursing perspective.
    Kay P
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
    Tsakonas G; Kosmas C
    J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the treatment of breast cancer.
    Moulder S; Hortobagyi GN
    Clin Pharmacol Ther; 2008 Jan; 83(1):26-36. PubMed ID: 18091763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.
    Ocaña A; Pandiella A
    Clin Cancer Res; 2008 Feb; 14(4):961-70. PubMed ID: 18281527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
    Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
    IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
    Gligorov J; Lotz JP
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
    Markman M
    Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
    Erman M
    J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological therapy of breast cancer: recent clinical applications.
    Baar J
    Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.
    Adams R; Maughan T
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):503-18. PubMed ID: 17428171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining molecular therapeutics with radiotherapy for head and neck cancer.
    Riesterer O; Milas L; Ang KK
    J Surg Oncol; 2008 Jun; 97(8):708-11. PubMed ID: 18493923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.